TSLP and asthma: The phase 2b PATHWAY study demonstrated that blocking TSLP with tezepelumab may be an effective strategy for the treatment of severe, uncontrolled asthma, with reductions in exacerbations observed irrespective of baseline inflammation status [28, 36].